Tradestie Institutional Equity Comparison Engine
SANA vs CCCC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CCCC Overall Edge
CCCC Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to C4 Therapeutics, Inc. (CCCC) driven by superior Momentum & Technical, Options & Structure while SANA counters with relative strength in Growth & Margin. Fundamentally, SANA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CCCC at N/M Forward P/E and -315.9% operating margin (-24.6% YoY). In options structure, SANA sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against CCCC sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SANA N/M vs CCCC N/M Fwd P/E
Growth & Margin Winner
SANA
Op Margin 0.0% vs -315.9% ยท YoY +0.0% vs -24.6%
Momentum & Technical Winner
CCCC
1Y -48.6% vs +8.2% ยท 52W Pos 1% vs 28%
Options & Structure Winner
CCCC
BREAKDOWN (4th %ile IV) vs BREAKDOWN (3rd %ile IV)
SANA
NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap
$605.3M
1M Return
-17.18%
1Y Return
-48.63%
Forward P/E
N/M
Unified AI Score
44.3 / 100
HOLD
Tech 33.0
Fund 51.0
Flow 66.0
Mom 60.0
CCCC
NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.65
-3.99% 1D
Market Cap
$362.4M
1M Return
-4.16%
1Y Return
+8.16%
Forward P/E
N/M
Unified AI Score
57.2 / 100
HOLD
Tech 35.0
Fund 52.0
Flow 68.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SANA -48.63%
CCCC +8.16%
Spread: +56.79 pp (CCCC Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SANA TTM Op. Margin: 0.0%
CCCC TTM Op. Margin: -315.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs CCCC. Trailing 12-month operating profitability (SANA 0.0% vs CCCC -315.9%) and valuation multiples (SANA N/M vs CCCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SANA | CCCC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $605.3M | $362.4M | Larger Scale | SANA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -24.6% | Higher Growth | SANA |
| Operating Margin (TTM) Profitability | 0.0% | -315.9% | Higher Margin | SANA |
| Net Profit Margin Profitability | 0.0% | -282.2% | Higher Margin | SANA |
| Return on Equity (ROE) Capital Efficiency | -79.5% | -47.6% | Higher ROE | CCCC |
| 52-Week Range Position Momentum | 1% ($2โ$5) | 28% ($2โ$5) | Stronger Trend | CCCC |
| Beta / 30D Volatility Risk Regime | 1.82ฮฒ ยท 78% Vol | 1.46ฮฒ ยท 69% Vol | Lower Realized Risk | CCCC |
| Unified Institutional Score Composite Signal | 44.3 / 100 (HOLD) | 57.2 / 100 (HOLD) | Higher Composite | CCCC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SANA vs CCCC Buy Guide
SANA
BREAKDOWN
57d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
4th %ile
IV Regime
Compressed (<25th %ile)
CCCC
BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SANA nor CCCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.